Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03588819 Recruiting - Prostate Cancer Clinical Trials

Stereotactic MRI-Guided Radiation for Localized Prostate Cancer

2SMART
Start date: April 23, 2018
Phase: N/A
Study type: Interventional

This single arm, prospective study will determine the prostate-specific quality of life (QOL) of patients undergoing undergoing a 2 fraction MRI-guided stereotactic ablative body radiation (SABR) protocol. We propose prescribing a prostate dose of 26 Gy in 2 fractions and a dose of up to 32 Gy to the dominant intraprostatic lesion (DIL) in 2 fractions over one week.

NCT ID: NCT03585660 Recruiting - Prostate Cancer Clinical Trials

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

Start date: June 19, 2018
Phase: N/A
Study type: Interventional

The purpose of the proposed research is to test and validate an artificial intelligence-based Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).

NCT ID: NCT03580239 Not yet recruiting - Prostate Cancer Clinical Trials

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

Investigators seek a new therapeutic strategy for castrated resistant prostate cancer(CRPC) patients with PI3K-AKT-mTOR signaling pathway deficiency by next generation sequencing(NGS).

NCT ID: NCT03579654 Not yet recruiting - Prostate Cancer Clinical Trials

Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

Start date: August 15, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with low-risk localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years following administration of Proscavax or active surveillance, the effect of the vaccine on prostate-specific antigen (PSA) doubling time and the assessment of adverse events in these patients. Eligible patients in this study will include men who are 18 years and older and who have a previously untreated early stage prostate cancer regardless of the date of diagnosis.

NCT ID: NCT03575832 Recruiting - Prostate Cancer Clinical Trials

Watchful Living: A Lifestyle Intervention for Black Prostate Cancer Patients on Active Surveillance and Their Partners

Start date: January 25, 2018
Phase: N/A
Study type: Interventional

The goal of this study is to learn if a social support lifestyle intervention (called Watchful Living) can help African American prostate cancer patients and their partners improve their quality of life, physical activity, diet, and inflammation. This is an investigational study. Up to 80 participants (40 patients and their partners) will be enrolled in this part of the study. All will take part at MD Anderson.

NCT ID: NCT03574571 Recruiting - Prostate Cancer Clinical Trials

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Start date: June 19, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

NCT ID: NCT03573011 Recruiting - Prostate Cancer Clinical Trials

PSMA PET/CT for Prostate Cancer

NGP2
Start date: June 15, 2018
Phase: Phase 2
Study type: Interventional

Prostate cancer is the most frequently occurring male cancer in Belgium. Patients who have been treated for prostate cancer, i.e. by surgery and/or radiotherapy, in a substantial degree suffer from a tumor recurrence, often diagnosed by an increase in serum tumor marker Prostate Specific Antigen (PSA) within the first few years. In these patients with evidence of a tumor recurrence after primary treatment, it is important to most exactly define the location(s) of tumor, to guide appropriate therapy by surgery, radiotherapy and/or hormonotherapy. In so-called oligo-metastatic disease targeted therapy may still be curative and prevent the disease from spreading to distant locations. Therefore it is of paramount importance to have an accurate tool of medical imaging to localize all possible locations to be treated.

NCT ID: NCT03572621 Recruiting - Prostate Cancer Clinical Trials

Development and Evaluation of a Therapeutic Education Intervention in Prostate Cancer Patients Treated With Radical Prostatectomy to Improve Their Sexuality

PRODUCAN
Start date: July 2018
Phase: N/A
Study type: Interventional

Prostate cancer is the most common cancer in France (54,000 cases in 2011). About 20,000 radical prostatectomies (PR) per year are performed. Despite the progress of PR over the past 20 years, the rate of erectile dysfunction post PR varies between 30 and 90% and only 16% of operated men recover their pre-treatment erections. There is currently no validated post-prostatectomy rehabilitation protocol. The associations of patients, including the National Association of Prostate Cancer Patients have a very strong demand for treatment of sexual problems after treatment.

NCT ID: NCT03572478 Not yet recruiting - Prostate Cancer Clinical Trials

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Start date: November 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic castration resistant prostate cancer (mCRPC) and metastatic/recurrent endometrial cancer. In the phase 1 portion, the safety of the combination dosing will be determined. If the combination dosing is determined to be safe and feasible, the study will move onto phase 2a. In the phase 2a portion, participants will be randomized to receive either: rucaparib alone, nivolumab alone, or combination therapy (rucaparib and nivolumab).

NCT ID: NCT03572387 Recruiting - Prostate Cancer Clinical Trials

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Start date: June 25, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, randomized, cross-over, pilot study of reprogramming therapy in patients with recurrent PCa based on rising PSA only. The primary objectives are to compare the disease progression-free rate at the end of 12 weeks between 5-AZA+ATRA and no therapy and to assess safety of the 5-AZA and ATRA combination. All study enrollees will receive Lupron. After one month, they will be assigned in a 1:1 randomization to either the `5-AZA+ATRA' group or the `no therapy' group. Patients in the `5-AZA + ATRA' group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles. Patients will initially be observed for 3 cycles under either no therapy or combination therapy, before crossing over to receive the opposite treatment for another 3 cycles in the absence of prohibitive toxicities. After the treatment period, all patients will be followed for a total of 24 months from the start of the study or until the events leading to discontinuation are observed.